Evaluation of a novel particle-based assay for detecting SLE-related autoantibodies
Daniel Lorca-Arce,
Albert Pérez-Isidro,
Judit Becerra,
Maria José Martínez,
Noemí De Moner,
Roberto Ríos-Garcés,
Sergio Prieto-González,
Gerard Espinosa,
Ricard Cervera,
Carmen Andalucía,
Odette Viñas-Gomis,
Estibaliz Ruiz-Ortiz
Affiliations
Daniel Lorca-Arce
Immunology Department, Centre Diagnostic Biomèdic CDB, Hospital Clínic de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Corresponding author. Immunology Department, Centre Diagnostic Biomèdic CDB, Hospital Clínic de Barcelona, C. de Villarroel, 170, 08036 Barcelona, Spain.
Albert Pérez-Isidro
Immunology Department, Centre Diagnostic Biomèdic CDB, Hospital Clínic de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
Judit Becerra
Immunology Department, Centre Diagnostic Biomèdic CDB, Hospital Clínic de Barcelona, Barcelona, Spain
Maria José Martínez
Immunology Department, Centre Diagnostic Biomèdic CDB, Hospital Clínic de Barcelona, Barcelona, Spain
Noemí De Moner
Immunology Department, Centre Diagnostic Biomèdic CDB, Hospital Clínic de Barcelona, Barcelona, Spain
Roberto Ríos-Garcés
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERNReCONNET, Hospital Clínic, Barcelona, Catalonia, Spain
Sergio Prieto-González
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERNReCONNET, Hospital Clínic, Barcelona, Catalonia, Spain
Gerard Espinosa
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERNReCONNET, Hospital Clínic, Barcelona, Catalonia, Spain
Ricard Cervera
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERNReCONNET, Hospital Clínic, Barcelona, Catalonia, Spain
Carmen Andalucía
Research and Development, Headquarters & Technology Center Autoimmunity, Werfen, San Diego, CA, USA
Odette Viñas-Gomis
Immunology Department, Centre Diagnostic Biomèdic CDB, Hospital Clínic de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
Estibaliz Ruiz-Ortiz
Immunology Department, Centre Diagnostic Biomèdic CDB, Hospital Clínic de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
Anti-dsDNA, anti-Sm, and anti-ribosomal-P autoantibodies are hallmarks of systemic lupus erythematosus (SLE), being anti-dsDNA and anti-Sm included in 2019-ACR/EULAR SLE-Classification Criteria. Enzyme-linked (ELISA) and chemiluminescence assays (CIA) are widely established in immunology laboratories, but new technologies, such as particle-based multi-analyte technology (PMAT), are nowadays available. The present study aimed to compare the presence of anti-dsDNA and anti-Sm autoantibodies measured by CIA and PMAT and analyze diagnostic and clinical SLE activity performance. Anti-ribosomal-P autoantibodies by PMAT were also included. Consequently, anti-dsDNA and anti-Sm detected by CIA showed substantial agreement with PMAT (Cohen's kappa = 0.662 and 0.671, respectively). Anti-dsDNA autoantibodies measured by PMAT showed a positive correlation with clinical SLEDAI-2K (p < 0.001) and a negative correlation with complement consumption (p < 0.001). Anti-Sm and anti-ribosomal-P autoantibodies showed a positive correlation with SLEDAI-2K (p < 0.001 and p = 0.001, respectively) and a negative correlation with complement consumption (p < 0.001 and p = 0.001, respectively). Finally, anti-Sm autoantibodies were associated with renal involvement (p < 0.05).